Pulmonary Arterial Hypertension - Epidemiology Forecast to 2027

Publication ID:
DEL0618034

Publication Date:
June 28, 2018

Pages:
50

Publisher:
Delveinsight

Region:
Global [1]

$3,250.00

Publication License Type *
- Single User License (PDF), $3,250.00
- Site License (PDF), $6,500.00
- Global License (PDF), $9,750.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.
Description:
DelveInsight’s ‘Pulmonary Arterial Hypertension - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Pulmonary Arterial Hypertension in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Pulmonary Arterial Hypertension Epidemiology
The Pulmonary Arterial Hypertension (PAH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Pulmonary Arterial Hypertension are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Pulmonary Arterial Hypertension Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, sex-specific prevalent cases, and sub-type specific prevalent cases) scenario of Pulmonary Arterial Hypertension (PAH)in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the total number of prevalent population of Pulmonary Arterial Hypertension (PAH) was found to be more than 70,000 in 7MM, in the year 2016. Women account for 70% of the total prevalent cases.

Report Scope
• The report covers detailed overview of Pulmonary Arterial Hypertension explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Pulmonary Arterial Hypertension in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the disease epidemiology segmented by total prevalent population, gender specific prevalence, sub-type specific prevalence, diagnosed pool and treatable population of PAH in
Key strengths

- 10 Year Forecast of Pulmonary Arterial Hypertension epidemiology
- 7MM Coverage
- Total Prevalent Cases of PAH
- Prevalent Cases according to segmentation: Gender-specific prevalence and subtype specific prevalence
- Diagnosed and treatable cases of PAH

Key assessments

- Patient Segmentation
- Disease Risk & Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population

Please Note - This report will available in 1 working day (24 hrs) after purchase.

Table Of Contents:

1. Report Introduction
2. Pulmonary Arterial Hypertension (PAH): Overview
   2.1. Signs and Symptoms
   2.2. Classification of Pulmonary Arterial Hypertension (PAH)
   2.3. Functional Classification of PAH
   2.4. Etiology
   2.5. Risk factors
   2.6. Pathophysiology
   2.7. Diagnosis
   2.8. Treatment
3. Epidemiology and Patient Population
   3.1. Key Points
   3.2. Population and Forecast Parameters
   3.3. Prevalent Population of Pulmonary Arterial Hypertension (PAH) in 7MM
      3.3.1. United States
         3.3.1.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
         3.3.1.2. Sub-type Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
         3.3.1.3. Gender Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
      3.3.2. Germany
         3.3.2.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
         3.3.2.2. Sub-type Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
         3.3.2.3. Gender Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
      3.3.3. France
3.3.3.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
3.3.3.2. Sub-type Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
3.3.3.3. Gender Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
3.3.4. Italy
3.3.4.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
3.3.4.2. Sub-type Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
3.3.4.3. Gender Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
3.3.5. Spain
3.3.5.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
3.3.5.2. Sub-type Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
3.3.5.3. Gender Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
3.3.6. United Kingdom
3.3.6.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
3.3.6.2. Sub-type Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
3.3.6.3. Gender Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
3.3.7. Japan
3.3.7.1. Prevalent Population of Pulmonary Arterial Hypertension (PAH)
3.3.7.2. Sub-type Specific Prevalent Population of Pulmonary Arterial Hypertension (PAH)
3.3.7.3. Gender Specific Prevalent Population Pulmonary Arterial Hypertension (PAH)
4. Treatment Algorithm
4.1. United States
4.1.1. CHEST Guidelines
4.2. Europe
4.2.1. European Society of Cardiology (ESC) and of the European Respiratory Society (ERS) Guidelines
5. Unmet Needs
6. Report Methodology
6.1. Sources Used
7. DelveInsight Capabilities
8. Disclaimer
9. About DelveInsight

List of Tables
Table 1: Total Prevalent Population of PAH in 7 MM (2016-2027)
Table 2: Prevalent Population of PAH in United States (2016-2027)
Table 3: Sub-type Specific Population of PAH in United States (2016-2027)
Table 4: Gender Specific Population of PAH in United States (2016-2027)
Table 5: Prevalent Population of PAH in Germany (2016-2027)
Table 6: Sub-type Specific Population of PAH in Germany (2016-2027)
Table 7: Gender Specific Population of PAH in Germany (2016-2027)
Table 8: Prevalent Population of PAH in France (2016-2027)
Table 9: Sub-type Specific Population of PAH in France (2016-2027)
Table 10: Gender Specific Population of PAH in France (2016-2027)
Table 11: Prevalent Population of PAH in Italy (2016-2027)
Table 12: Sub-type Specific Population of PAH in Italy (2016-2027)
Table 13: Gender Specific Population of PAH in Italy (2016-2027)
Table 14: Prevalent Population of PAH in Spain (2016-2027)
Table 15: Sub-type Specific Prevalent Population of PAH in Spain (2016-2027)
Table 16: Gender Specific Population of PAH in Spain (2016-2027)
Table 17: Prevalent Population of PAH in United Kingdom (2016-2027)
Table 18: Sub-type Specific Population of PAH in United Kingdom (2016-2027)
Table 19: Gender Specific Population of PAH in United Kingdom (2016-2027)
Table 20: Prevalent Population of PAH in Japan (2016-2027)
Table 21: Sub-type Specific Population of PAH in Japan (2016-2027)
Table 22: Gender Specific Population of PAH in Japan (2016-2027)

List of Figures
Figure 1: Classification of Pulmonary Arterial Hypertension (PAH)
Figure 2: Functional Classification of PAH
Figure 3: Risk Factors of Pulmonary Arterial Hypertension
Figure 4: Pathophysiology of Pulmonary Arterial Hypertension (PAH)
Figure 5: Diagnosis Algorithm of Pulmonary Arterial Hypertension (PAH)
Figure 6: Treatment Options for Pulmonary Arterial Hypertension (PAH)
Figure 7: Prevalent Population Of PAH in 7 MM (2016-2027)
Figure 8: Prevalent Population of PAH in United States (2016-2027)
Figure 9: Sub-type Specific Prevalent Population of PAH in United States (2016-2027)
Figure 10: Gender Specific Prevalent Population of PAH in United States (2016-2027)
Figure 11: Prevalent Population of PAH in Germany (2016-2027)
Figure 12: Sub-type Specific Prevalent Population of PAH in Germany (2016-2027)
Figure 13: Gender Specific Prevalent Population of PAH in Germany (2016-2027)
Figure 14: Prevalent Population of PAH in France (2016-2027)
Figure 15: Sub-type Specific Prevalent Population of PAH in France (2016-2027)
Figure 16: Gender Specific Prevalent Population of PAH in France (2016-2027)
Figure 17: Prevalent Population of PAH in Italy (2016-2027)
Figure 18: Sub-type Specific Prevalent Population of PAH in Italy (2016-2027)
Figure 19: Gender Specific Prevalent Population of PAH in Italy (2016-2027)
Figure 20: Prevalent Population of PAH in Spain (2016-2027)
Figure 21: Sub-type Specific Prevalent Population of PAH in Spain (2016-2027)
Figure 22: Gender Specific Prevalent Population of PAH in Spain (2016-2027)
Figure 23: Prevalent Population of PAH in United Kingdom (2016-2027)
Figure 24: Sub-type Specific Prevalent Population of PAH in United Kingdom (2016-2027)
License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or
persons outside of the organization.

- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.